Overview

The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC

Status:
Not yet recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of envafolimab combined with concurrent chemoradiotherapy in limited stage small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences